B 6122
Alternative Names: B-6122Latest Information Update: 09 Apr 2025
At a glance
- Originator Samyang Biopharmaceuticals Corporation
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 09 Apr 2025 Discontinued for Cancer in South Korea (Parenteral) (Samyang Biopharmaceuticals Corporation pipeline; April 2025)
- 28 Mar 2020 No recent reports of development identified for research development in Cancer in South Korea (Parenteral, Injection)
- 22 Feb 2016 Early research in Cancer in South Korea (Parenteral)